anti-CD44 monoclonals (Yissum/Coulter)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-CD44 monoclonals (Yissum/Coulter)
Drug Alias Namerheumatoid arthritis therapy (Yissum/Coulter)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionCD44 antigen inhibitors
TargetsCD44 antigen
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIsrael
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesYissum Research Development Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCoulter Pharmaceutical IncYissum Research Development Company
Active IndicationsN/A
Inactive IndicationsArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A